Advances in the field of tumor biology have identified that tumor cells co-opt developmental signaling pathways of embryonic stem cells and thus gain the ability to proliferate, differentiate and alter cell-cell interactions. One such pathway is the Wnt/b-catenin signaling pathway. High levels of EMMPRIN expression have been shown to correlate with poor prognosis and metastasis in a broad range of tumors. Although a variety of functions are attributed to EMMPRIN in tumorigenesis, the specific mechanism(s) through which it can exert its effects have not been elucidated, until now. In this study, we identify EMMPRIN as a novel regulator of the canonical Wnt/ b-catenin signaling pathway in lung cancer. Increasing EMMPRIN expression levels in lung cancer epithelial cells upregulated the b-catenin signaling pathway and silencing EMMPRIN inhibited b-catenin signaling, cell migration, proliferation, anchorage-independent growth and tumor growth in a mouse tumor xenograft model. These results provide a compelling rationale for targeting EMMPRIN for anticancer therapies. Understanding the molecular mechanisms driving EMMPRIN-induced lung tumorigenesis will provide enormous benefits in developing new therapeutic treatments for this and other forms of cancer.
Introduction
Lung cancer is the most commonly diagnosed cancer (1.35 million cases) and is the leading cause of cancer death worldwide, with over 1.1 million deaths (Parkin et al., 2005) . Despite much research, we do not yet have drugs adequate for treating lung cancer. A better understanding of the molecular mechanisms driving lung tumorigenesis is crucial and will provide enormous benefits in developing new therapeutic treatments for this and other forms of cancer.
A common concept in the field of tumor biology is that metastatic cells co-opt stem cell-like developmental and inflammatory signaling pathways and thus gain the ability to proliferate, differentiate and alter cell-cell interactions. One such pathway that has been shown to have a critical role in a wide range of tumors, including lung cancer, is the Wnt/b-catenin signaling pathway (Uematsu et al., 2003; Reya and Clevers, 2005) . During embryonic development, the Wnt/b-catenin signaling pathway has been shown to regulate cell proliferation, apoptosis, migration and differentiation (Logan and Nusse, 2004) . In the lung, Wnt signaling is crucial for lung development (Bonner et al., 2003; Daniel et al., 2006) . However, unscheduled reactivation of this embryonic signaling pathway in adult cells can lead to inflammatory diseases, such as pulmonary fibrosis and cancer transformation (Morrisey, 2003; Polakis, 2007; Klaus and Birchmeier, 2008; Van Scoyk et al., 2008) .
The central component of the canonical Wnt cascade is b-catenin. In cancer, the dysregulation of this pathway can lead to the entry and accumulation of b-catenin into the nucleus. Once there, b-catenin cooperates with Tcf/ Lef DNA-binding proteins to turn on a program of gene expression that promotes tumorigenesis. Consequently, the aberrant expression of molecules involved in the Wnt signaling pathway has acquired tremendous interest and are being evaluated as targets for cancer therapy (Weeraratna et al., 2002; Moon et al., 2004; Sato et al., 2004; Taketo, 2004) . Thus, identifying novel factors that can regulate the Wnt/b-catenin signaling pathway is extremely desirable and have the potential to be used as targeted therapies in cancer treatment.
Extracellular matrix metalloproteinase inducer (EMMPRIN), also known as CD147 (basigin in mice), is a heavily glycosylated type I transmembrane glycoprotein. It is believed to have a significant role in the development, differentiation and remodeling of many normal tissues including the lung, thymus, retina, skin, cornea and nervous system (Renno et al., 2002; Betsuyaku et al., 2003; Gabison et al., 2005; Nabeshima et al., 2006) . However, it is in the field of cancer that EMMPRIN has garnered most interest because of its consistently high levels of expression on the surface of various tumors, including lung tumors, and because of its correlation with poor prognosis (Caudroy et al., 1999; Davidson et al., 2003; Yan et al., 2005; Riethdorf et al., 2006; Als et al., 2007; Sienel et al., 2008) . EMMPRIN expression has also been linked to tumor metastasis as it is one of the most constantly upregulated mRNAs in bone marrow metastatic cells in lung, prostate and breast cancer (Klein et al., 2002; Reimers et al., 2004) . In the breast cancer metastasis study, over 90% of micrometastatic cells isolated from the bone marrow of 55 breast cancer patients were found to be EMMPRIN positive and EMMPRIN was the most abundantly expressed marker in all the patient samples examined (Reimers et al., 2004) .
To date, EMMPRIN is thought to affect tumor progression through its ability to stimulate MMP expression (Biswas et al., 1995; Guo et al., 1997; Sidhu et al., 2004) ; more recently, it has been shown that EMMPRIN can also regulate VEGF expression (Tang et al., 2005) , a gene known to control angiogenesis. Yet, despite the relative abundance of EMMPRIN as a tumor cell surface marker, it has not been vigorously pursued as a therapeutic target for cancer, in part because of the fact that EMMPRIN's upregulation of MMPs and VEGF is relatively modest, and perhaps more importantly because of the failure of MMP inhibitors as cancer therapeutics in clinical trials (reviewed in Coussens et al., 2002; Overall and LopezOtin, 2002; Overall and Kleifeld, 2006) .
In this study, we show that EMMPRIN has a central role in lung tumor progression through its ability to enhance cell proliferation, migration, anchorage-independent growth and cell survival; processes that we show are not dependent on the regulation of MMPs. Our results illustrate that EMMPRIN has a more fundamental role in tumorigenesis than earlier realized by its ability to regulate Wnt/b-catenin signaling in cancer.
Results

Phenotypic changes induced by increasing EMMPRIN expression levels in tumor cells
In a screen of primary human bronchial epithelial cells (HBE) and lung tumor cell lines, we observed that EMMPRIN was expressed at high levels in all tumor cell lines examined. In contrast, normal primary HBE cells exhibited little or no EMMPRIN expression ( Figure 1a) . To study the effect of EMMPRIN in tumor cells, we stably transfected a human EMMPRIN expression vector into two lung epithelial tumor cell lines (NCI-H460 and NCI-H292). These cell lines have been well characterized earlier by our group (Lemjabbar et al., 2003; Sidhu et al., 2004; LemjabbarAlaoui et al., 2010) . Despite already high levels of endogenous EMMPRIN expression in these cells, expression of recombinant EMMPRIN resulted in a two-to threefold increase in EMMPRIN protein expression levels (Figure 1b) .
To characterize any morphological changes induced by EMMPRIN overexpression, we carried out phasecontrast microscopy on NCI-H460 and NCI-H292 parental cells (H460 and H292), cells stably transfected with human rEMMPRIN (EMP) and cells stably transfected with vector alone (CTL). Increased EMM-PRIN expression led to a change in cell morphology, with a decrease in cell-cell contacts and an increase in lamellipodia formation with a concurrent increase in cell motility (Figure 1c) . Changes in H460 cell morphology were more pronounced than those observed in H292 cells. Changes in motility were confirmed by migration assays carried out using Boyden chambers with 8-mmpore membrane inserts. Cell suspensions were added to the upper chamber and the numbers of migrating cells found on the lower surface of the membrane inserts were counted 24 h later. Typically, a 300-400% increase in migration was observed in H460EMP cells as compared with H460CTL and nontransfected H460 parental cells (Figure 1d ), whereas H292EMP cells displayed a 67% increase in cell migration.
EMMPRIN overexpression stimulates anchorage-independent growth and cell proliferation We next addressed the question whether EMMPRINinduced morphological changes had any consequences on cell survival and proliferation. Using soft-agar assays, we examined the effect of EMMPRIN overexpression on anchorage-independent growth as a characteristic phenotype of metastatic tumor cells. Typically, three times as many colonies were observed in soft-agar assays carried out on H460EMP and H292EMP cells as compared with CTL and untransfected parental cells after 10 days of culture (Figure 2a ). An increase in average colony size was also observed in both cell lines (data not shown). Cell proliferation assays carried out by FACS analyses on the incorporation of 5-bromodeoxyuridine (BrdU) in these cells showed that EMMPRIN significantly enhanced cell proliferation. On an average, H460EMP cells had a 126% increase in BrdU uptake compared with H460CTL cells, and a 48% increase in BrdU uptake was observed in H292EMP cells (Figure 2b) . No statistically significant differences were observed between parental cells and vector control-transfected cells in the soft-agar growth assays and proliferation assays.
EMMPRIN regulates b-catenin signaling
The ability of EMMPRIN to enhance cell migration, anchorage-independent growth and cell proliferation suggested a broader role for EMMPRIN in epithelial tumor cells than the regulation of MMPs. We hypothesized that EMMPRIN has a more fundamental role in cell proliferation and cell survival signaling pathways than earlier realized. Owing to the phenotypic changes observed, that is increase in cell motility and loss of cellcell contacts (Figure 1d) , we examined the expression of E-cadherin and b-catenin, which are markers for cell adhesion and important factors in the canonical Wnt signaling pathway.
Western blot and immunostaining analysis showed a loss of E-cadherin expression in H292EMP cells as compared with parental and vector control cells (Figure 3a ). E-cadherin expression was not detected in H460 cells (data not shown). Immunostaining studies showed an accumulation of b-catenin in the nucleus of EMMPRIN-overexpressing cells (Figure 3b ). Accumulation of b-catenin in the nucleus of H460 cells was less apparent than that in H292 cells, because of lower amounts of total b-catenin in H460 cells. However, western blotting of protein compartmental extractions of H460 and H292 cell lysates verified the increase in b-catenin levels in the nuclear fraction of EMMPRINexpressing cells (Figure 3c ). Moreover, the nuclear fractions for EMMPRIN-overexpressing cells also contained more 'functional' b-catenin as confirmed by immunoblotting with an antibody specific for active b-catenin, nonphosphorylated on Ser37 or Thr41 (Staal et al., 2002; Figure 3c) . No differences in b-catenin immunostaining were observed between parental and control-transfected cells.
To validate the functional significance of b-catenin translocation to the nucleus, Wnt signaling activity was measured by luciferase expression controlled by concatemers of 'TCF optimal sites' (TOPFLASH), or, as a negative control, concatemers of TCF 'far from optimal sites' (FOPFLASH), a standard method for measuring b-catenin-dependent transcriptional activation (Pasca di Magliano et al., 2007) . In H460 cells, EMMPRIN overexpression was found to induce a 38% increase in TOPFLASH luciferase reporter activity when compared with parental and control-transfected cells (Figure 3d) . In H292EMP cells, typically a threefold activation of TOPFLASH reporter was observed (Figure 3d ). Boon et al., 2004; Koornstra et al., 2005) . Sulindac sulfone belongs to the family of nonsteroidal anti-inflammatory drugs and has been shown in vitro and in vivo to induce b-catenin degradation through proteosome-and caspase-dependent mechanisms (Klaus and Birchmeier, 2008) . Sulindac sulfone can also target COX2; therefore, NS398, a COX2 inhibitor, was used as a control to confirm the specificity of sulindac sulfone activity. Cells transfected with siRNA oligos or treated with chemical inhibitors were assayed for cell growth 3 days after transfection using the cell titer blue assay.
Cells transiently transfected with b-catenin siRNA oligos displayed an inhibition of cell growth in H460 and H292 cells compared with cells transfected with control siRNA oligos (50% and 44% reduction in activity, respectively; Figure 4a ). The specificity of the bcatenin siRNA oligos was confirmed by western blot analysis, showing a loss of b-catenin protein in lysates from cells transiently transfected with b-catenin-specific siRNA oligos only (Supplementary Figure 1a) . The efficacy of b-catenin and control siRNA oligos on TOPFLASH luciferase reporter signaling was also examined. A significant reduction in TOPFLASH activity was observed in cells treated with b-catenin siRNA oligos as compared with control siRNA oligos with a 72% (H460) and 66% (H292) reduction in reporter activity (Supplementary Figure 1b) .
Consistent with the b-catenin siRNA oligo data, sulindac sulfone inhibited cell growth by approximately 51% in H460 cells and by 42% in H292 cells (Figure 4b ), whereas the COX2 inhibitor, NS398, had no effect.
EMMPRINs' regulation of b-catenin signaling is MMP independent We next determined whether MMPs have a role in EMMPRIN-mediated cell growth and Wnt/b-catenin signaling, as they have often been described as the principal downstream targets of EMMPRIN expression. Despite using three well-defined MMP inhibitors, TIMP1, MMP inhibitor set II and set III (Calbiochem, San Diego, CA, USA), it can be clearly seen that MMP inhibitors had no inhibitory effect on TOPFLASH reporter activity; rather, they actually increased reporter activity in EMMPRIN-overexpressing cells (Figure 4c ). MMP inhibitors also had no inhibitory effects on anchorage-independent growth, as determined by colony counts of tumor cells after 10 days in soft-agar growth assays (Figure 4d ; data shown for the broad range MMP inhibitor TIMP1 only). Furthermore, MMP inhibitors also had no effect on EMMPRIN-induced cell viability and cell proliferation, as measured by cell titer blue assays (Figure 4b ; data shown for TIMP1 only).
Silencing EMMPRIN inhibits Wnt/b-catenin signaling, cell growth, cell migration and induces apoptosis The above data show that EMMPRIN upregulation can lead to an increase in Wnt/b-catenin signaling and that Wnt/b-catenin signaling is important for cell growth in these tumor cell lines. We next addressed the question whether downregulation of EMMPRIN could affect Wnt/b-catenin signaling. Several EMMPRIN siRNA oligos were designed and evaluated for their ability to silence EMMPRIN in H460 and H292 cells (data not shown). The two most effective EMPsi RNA oligos (EMPsi1 and EMPsi2, see Materials and methods) were also tested for their ability to affect b-catenin signaling. EMMPRIN siRNA oligos significantly inhibited TOP-FLASH reporter activity; EMPsi1 siRNA oligos had, on an average, a 60% (H460) and 55% (H292) reduction in TOPFLASH reporter activity and EMPsi2 siRNA oligos consistently displayed a 43% (H460) and 50% (H292) reduction compared with control siRNA oligos (Supplementary Figure 2a) . EMMPRIN siRNA oligos had an inhibitory effect on TOPFLASH reporter activity similar to that seen with b-catenin siRNA oligos (Supplementary Figures 1b and 2a) .
To carry out long-term studies on the effects of EMMPRIN inhibition on Wnt/b-catenin signaling and tumor cell growth, we used a lentiviral expression vector system (pLVTHM) driving the production of short hairpin RNA (shRNA) (Wiznerowicz and Trono, 2003) . This lentiviral system also incorporates a reporter gene for enhanced green fluorescent protein for the labeling of transduced cells. The sequence of the most efficient EMMPRIN siRNA oligo (EMPsi1) was used to generate EMMPRIN shRNA (pLVshEMP), and the control siRNA oligo sequence used in the transient transfection studies was used as control shRNA (pLVshCTL, see Materials and methods). H460 and H292 cells were successfully transduced, as observed by FACs analysis for GFP expression (97-99%, data not shown), and then used for subsequent studies.
Western blotting of lysates from H460 and H292 cells expressing shEMP revealed a significant inhibition (typically 50-80%) of EMMPRIN protein levels (Figure 5a ). Cells expressing shCTL had no effect on EMMPRIN expression. Furthermore, cells expressing shEMP exhibited a decrease in Wnt/b-catenin signaling, as measured by TOPFLASH luciferase reporter activity, with a 68% reduction in H460 cells and a 56% reduction in H292 cells (Figure 5b ). Western blotting of nuclear fractions taken from cells expressing EMP shRNA also showed a decrease in b-catenin and active b-catenin levels in the nucleus, compared with CTL shRNA-expressing cells (Supplementary Figure 2b) . Sulindac sulfone significantly reduces cell growth/proliferation in H460 and H292 cells as measured using cell titer blue assays. The COX2 inhibitor, NS398, and the MMP inhibitor, TIMP1, had no effect on cell growth. Cells were assayed 3 days after treatment. *Statistically significant changes as compared with NS398-treated cells, Po0.001 in H460 and Po0.012 in H292 cells. (c) Three well-defined MMP inhibitors, TIMP1, MMP inhibitor set II and set III (Calbiochem), have no inhibitory effect on EMMPRIN-induced Wnt/b-catenin signaling as measured by TOPFLASH luciferase reporter activity. MMP inhibitors stimulate baseline reporter activity. (d) The MMP inhibitor TIMP1 has no inhibitory effects on EMMPRIN-induced anchorage-independent growth, as measured by colony counts in soft-agar growth assays pretreated with TIMP1.
We next quantified the effects of shEMP on cell migration, proliferation and anchorage-independent growth. Using transwell migration assays, a significant inhibition of cell migration was observed in cells expressing shEMP. An 81% decrease in migration was observed in H460-pLVshEMP cells and an 86% decrease in H292-pLVshEMP cells, compared with cells transduced with pLVshCTL (Figure 5c ). No statistically significant differences in cell migration were observed between pLV-shCTL cells and their parental counterparts.
Silencing of EMMPRIN expression also reduced the ability of the two lung cell lines to grow in soft agar.
Anchorage-independent growth was severely restricted, with a 71% decrease in H460-pLVshEMP cells and a 43% decrease in H292-pLVshEMP cells (Figure 5d ). No significant differences in anchorage-independent growth were observed in parental and shCTL-expressing cells.
Changes in cell proliferation were measured by FACs analysis of BrdU incorporation into cells. Cells expressing shEMP displayed a significant reduction of 65 and 33% in BrdU uptake in H460-and H292-pLVshEMP cells, respectively, compared with shCTL-expressing cells (Figure 5e ). Changes in cell death/apoptosis were also measured by FACs analysis of Annexin-V staining. Increased Annexin-V staining was observed in both H460-pLVshEMP and H292-pLVshEMP cells (59 and 36%, respectively), compared with control-transduced cells (Figure 5f ).
Wnt signaling mediates EMMPRIN's effects on tumor cell growth
To determine whether Wnt signaling directly mediates the effects of EMMPRIN on tumor cell growth, we assessed the effect of two different soluble extracellular inhibitors of Wnt (sFRP and WIF-1) in cell growth/ viability assays on H460 and H292 cells expressing CTL shRNA or EMP shRNA. Cells were treated with sFRP (3 mg/ml) or WIF-1 (3 mg/ml) on day 0 and day 2 and were assayed after 3 days of culture using the Cell Titer 96 Aqueous One Solution Cell Proliferation assay. CTL shRNA-expressing cells treated with sFRP and WIF-1 displayed an inhibition of cell growth in H460 and H292 cells, compared with untreated cells (30-40% reduction in growth). Silencing of EMMPRIN generated equivalent effects on cell growth/viability as that produced by the Wnt inhibitors (30-40%). More significantly, the extracellular Wnt inhibitors had no 'additive' inhibitory effect on cell growth in EMP shRNA-treated cells (Figure 6a ). These data provide strong evidence that an autocrine Wnt signaling pathway directly mediates the effects of EMMPRIN on tumor cell growth.
EMMPRIN shRNA inhibits tumor formation after transplantation into nude mice H460 and H292 cells readily form tumors in nude mice. To assess the effects of EMMPRIN silencing in vivo, we compared the tumorigenicity of H460 and H292 cells transduced with pLVshCTL and pLVshEMP in immunodeficient mice. Nude mice were subcutaneously injected with positively transduced cell populations as confirmed by GFP expression (B99%). Tumors were allowed to develop for 18 days and at the end of that period, animals were killed and tumors were dissected out and weighed. Cell lines transduced with shEMP generated greatly reduced tumor burdens, compared with shCTL-transduced cells. A 61 and 45% reduction in tumor weight was observed in H460-pLVshEMP and H292-pLVshEMP cells, respectively (Figure 6b and c) .
The above in vitro and in vivo experiments reinforce the fact that EMMPRIN is an important contributor to tumor viability through regulation of proliferation, survival and tumorigenicity. This role of EMMPRIN is mediated by its ability to function as a regulatory component of canonical Wnt/b-catenin signaling, a fundamental cell survival signaling pathway.
Discussion
EMMPRIN has long been thought to stimulate cell migration and invasion of tumor cells by stimulating the production of MMPs in adjacent fibroblasts. There is also growing evidence that EMMPRIN can function in an autocrine manner in some tumor cell lines and stimulate the production of MMP2, MMP9 and VEGF (Yan et al., 2005; Nabeshima et al., 2006; Tang et al., 2006) . More recently, various studies have suggested a broader role for EMMPRIN in tumor growth and multidrug resistance (Reimers et al., 2004; Yang et al., 2006; Wang et al., 2008) . Clearly, EMMPRIN has an important role in tumor biology, which extends beyond the role of regulating MMP expression.
To better understand the function of EMMPRIN in tumor biology, we thoroughly characterized the effect of EMMPRIN expression in lung carcinoma cell lines. Increased EMMPRIN expression was found to significantly enhance cell migration, proliferation and anchorage-independent growth, thus confirming an essential role for EMMPRIN in tumor biology. This result was surprising, as EMMPRIN expression levels are already very high in these cells. Thus, EMMPRIN expression seems to be rate limiting. We then set out to identify the mechanism by which EMMPRIN regulates such diverse functions. We hypothesized that EMMPRIN regulated fundamental developmental signaling pathways, the aberrant reactivation of which has been implicated in metastasis and cancer growth.
In this study, we discovered a hitherto unknown effect of EMMPRIN on the canonical Wnt/b-catenin signaling pathway. Increasing EMMPRIN expression in lung epithelial tumor cell lines increased Wnt/b-catenin signaling, as shown by the nuclear accumulation of active (nonphosphorylated) b-catenin in EMMPRINoverexpressing cells and increased TOPFLASH luciferase reporter activity (Figure 3) . That EMMPRIN has a regulatory role over Wnt/b-catenin signaling is reinforced by the data that EMMPRIN inhibition also leads to a drastic decrease in TOPFLASH luciferase reporter activity (see Figure 5b ; Supplementary Figure 2) . Indeed, the inhibition of cell growth by EMMPRIN siRNA oligos is similar to that seen by b-catenin siRNA oligos and the chemical Wnt inhibitor, sulindac sulfone (Figures 4a and b and 5e ). The significant inhibition of growth by b-catenin siRNA oligos or sulindac sulfone also confirms that the canonical Wnt/b-catenin signaling pathway is necessary for lung tumor cell growth/survival (Figures 4c and d) . Furthermore, in cell growth/viability assays, the extracellular Wnt inhibitors, sFRP and WIF-1, had no 'additive' inhibitory effects on cell growth in EMP shRNA-treated cells, which provide strong evidence that an autocrine Wnt signaling pathway directly mediates the effects of EMMPRIN on tumor cell growth (Figure 6a ). In concordance, EMMPRIN shRNA inhibited several important parameters necessary for tumor progression, such as cell proliferation, cell migration and anchorage-independent growth, and, in an in vivo xenograft model of tumorigenesis, significantly reduced tumor growth (Figure 5 and 6 ). Taken together, these results show that EMMPRIN, by regulating the canonical Wnt/b-catenin signaling pathway, has an important role in the maintenance, proliferation and survival of lung tumor epithelial cells.
In this study, we also attempted to determine the manner in which EMMPRIN regulates b-catenin signaling. MMPs have long been identified as genes that are upregulated by EMMPRIN, hence we were surprised to discover that several well-defined MMP inhibitors had no inhibitory effect on EMMPRINinduced changes in Wnt/b-catenin signaling (Figure 4 ). In addition, these MMP inhibitors had no inhibitory effect on important parameters of tumorigenesis such as anchorage-independent growth and proliferation (Figure 4 ). In contrast, TOPFLASH reporter activity was significantly increased after treatment of cells with MMP inhibitors. MMPs are degrading enzymes of the extracellular matrix and of cell surface components such as heparin proteogylcans. Heparin proteogylcans have important functions as coreceptors for growth factors and regulate the bioavailability of growth factors on the cell surface. Therefore, inhibition of MMPs might increase the amount of heparan sulfate-bound Wnt ligand on the cell surface and might, therefore, stimulate cellular signaling (Lin, 2004; Nawroth et al., 2008) . These results suggest that EMMPRIN-mediated regulation of b-catenin signaling is independent of MMP regulation and perhaps MMP expression is downstream of the Wnt/b-catenin signaling pathway. However, we cannot exclude the possibility that b-catenin signaling and MMP induction are stimulated independently through two distinct and separate pathways, although there is evidence that MMP expression can be stimulated by Wnt signaling (Roth et al., 2000; Soon et al., 2003; Lowy et al., 2006) .
As EMMPRIN is a transmembrane glycoprotein that can be released from the cell surface (Sidhu et al., 2004; Baj-Krzyworzeka et al., 2006; Millimaggi et al., 2007) , whether EMMPRIN functions in an autocrine or intracrine manner stills needs to be elucidated. Further investigations are required to identify the precise molecular mechanisms and interactions that control EMMPRIN's regulation of canonical Wnt/b-catenin signaling in tumor biology. One possibility is that EMMPRIN may directly interact with E-cadherin/ b-catenin complexes in the plasma membrane and, by destabilizing them, lead to an increase in free b-catenin. In H292 cells, we see a loss in E-cadherin staining from the cell surface on increased EMMPRIN expression (Figure 3a) , which lends credence to this hypothesis. However, H460 cells do not express E-cadherin and still show a reduction in b-catenin immunostaining at the cell surface.
Other possible mechanisms for EMMPRIN to regulate Wnt/b-catenin activity could arise from direct or indirect changes in plasma membrane dynamics induced by EMMPRIN clustering and microvesicle shedding. Earlier research by us, as well as by others, has shown that increasing EMMPRIN levels in cells can lead to EMMPRIN clustering in the plasma membrane and/or increased microvesicle shedding (Sidhu et al., 2004; Baj-Krzyworzeka et al., 2006; Millimaggi et al., 2007) . Direct changes in the plasma membrane could lead to EMMPRIN regulating b-catenin levels and cellcell contacts through activation of distinct cell-signaling pathways such as AKT and MAPK (Tang et al., 2006; Huang et al., 2008) . However, whether these pathways are upstream or downstream of Wnt/b-catenin signaling has yet to be established. Alternatively, EMMPRIN could increase the bioavailability of various factors in the extracellular milieu (such as Wnts) by increased microvesicle shedding (Bartscherer and Boutros, 2008; Gagliardi et al., 2008) .
Finally, EMMPRIN has been suggested to interact with a wide variety of molecules at the cell surface, such as cyclophilins, integrins, caveolin-1, monocarboxylate transporters (Berditchevski et al., 1997; Sun and Hemler, 2001; Deora et al., 2005; Yurchenko et al., 2005) and even an ability to oligomerize and dimerize in both a cis and trans manner (Fadool and Linser, 1996; Yu et al., 2008) . Determining which, if any, of these interactions are important for EMMPRIN's role in tumorigenesis warrants further investigation and is the basis of our current research.
Aberrant expression or mutations of several regulatory genes in the Wnt/b-catenin cell-signaling pathway have already been implicated in human tumor progression and are currently being evaluated as targets for cancer therapy (Moon et al., 2004; Taketo, 2004; Safholm et al., 2008) . However, identifying novel, critical upstream regulators of the Wnt/b-catenin signaling pathway is still extremely desirable.
In summary, we identify EMMPRIN as a novel regulator of the canonical Wnt/b-catenin signaling pathway in lung tumorigenesis. Increasing EMMPRIN levels in lung tumor epithelial cells leads to an enhancement in the metastatic potential of these cells through the upregulation of Wnt/b-catenin signaling. Moreover, inhibition of EMMPRIN using EMMPRIN shRNA drastically blocked this signaling pathway and inhibited several important parameters necessary for tumor progression, such as cell proliferation, cell migration and anchorage-independent growth. Finally, in vivo, using a subcutaneous xenograft tumor model in athymic mice, we show that EMMPRIN shRNA expression in tumor cells significantly reduced the growth of tumors arising from human lung tumor cells. Our results strengthen the proposal that EMMPRIN, because of its relative abundant expression and its accessibility as a cell surface molecule on a wide variety of tumors, would make an attractive target for the development of anticancer therapies such as inhibition by antibodies or small molecule inhibitors.
Materials and methods
Antibodies and reagents
The mouse monoclonal anti-EMMPRIN antibody was obtained from Biodesign International (Saco, Maine); E-cadherin and b-catenin monoclonal antibodies (mAbs) were from BD Biosciences (San Jose, CA, USA); active b-catenin (clone 8E7) and GAPDH mAbs were obtained from Millipore (Temecula, CA, USA); secondary Abs were from Jackson Immuno Research (West Grove, PA, USA); anti-mouse horseradish peroxidase-conjugated secondary antibodies were used for western blot analyses; secondary cy3-conjugated antibodies were used for immunofluorescence studies; TIMP1, MMP inhibitor set II and set III were obtained from Calbiochem; and sFRP-1 and WIF-1 were obtained from R&D Systems (Minneapolis, MN, USA).
Cell culture and lysate preparation NCI-H460 and NCI-H292 cells were originally obtained from American Type Culture Collection. Cells were grown to confluence in 75 cm 2 flasks (Falcon) in RPMI medium with 10% fetal bovine serum (FBS) at 37 1C under 5%CO 2 /95% atmosphere. Cell lysates were prepared by washing the cells in phosphate-buffered saline (PBS), before lysing in RIPA buffer (150 mM NaCl, 1% Triton X-100, 0.1% SDS, 50 mM Tris-HCl pH 7.5) containing a cocktail of complete proteinase inhibitors (Roche, Mannheim, Germany). For extracting specific protein compartments, we used the Compartmental Protein Extraction kit (Millipore, Billerica, MA, USA). Typically, 1 or 10 mg of total protein lysate was used for western blot analyses. Equal protein concentrations were loaded on the basis of quantification with the BCA Protein Assay (Pierce, Rockford, IL, USA) following the manufacturer's protocol. All experiments were carried out in triplicate.
Western blot analysis Samples were electrophoresed under nonreducing (for EMM-PRIN) or reducing (b-catenin, E-cadherin and GAPDH) conditions in 12% Tris-HCl Ready Gels (Bio-Rad, Hercules, CA, USA) and transferred to Hybond nitrocellulose paper (Amersham, Piscataway, NJ, USA). Nonspecific-binding sites were blocked by washing blots in 5% nonfat milk (Nestle) in PBS containing 0.1% Tween20 (PBST; Sigma, St Louis, MO, USA) for 1 h with shaking. Blots were incubated with primary antibody overnight at 4 1C, washed in PBST and incubated with horseradish peroxidase -conjugated secondary antibody for 1 h at room temperature. Blots were washed again before visualizing immunocomplexes using the ECL Western blotting kit (Amersham) and exposing to Hyperfilm (Amersham).
Plasmid and lentiviral expression constructs
Description is provided in Supplementary Information.
In vitro cell migration assays
Methodology is provided in Supplementary Information.
Colony formation in soft agar
BrdU incorporation assays
Cells were grown for 2 days and then pulsed with 10 mM BrdU during the final 2 h of culture. BrdU was detected with either a fluorescein isothiocyanate-conjugated or APC-conjugated anti-BrdU antibody (BD Biosciences, Bedford, MA, USA).
